ALKS vs NERV
ALKS: Alkermes is a neuroscience-focused biopharmaceutical company developing and commercializing therapeutic treatments for complex neurological and psychiatric disorders. NERV: A clinical-stage biotechnology company developing potential treatments for the negative symptoms of schizophrenia.
Side-by-side fundamentals
| Metric | ALKS | NERV | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $40.11 | $3.22 | |
| Market cap | $6.7B | $154M | |
| P/E as of 2026-10-08 | 104.21 | n/a | |
| Net margin FY2025, SEC XBRL | +16.4% | n/a | |
| Operating margin FY2025, SEC XBRL | +17.2% | n/a | |
| ROE FY2025, SEC XBRL | +13.3% | n/a | |
| ROA FY2025, SEC XBRL | +9.7% | -299.5% | ALKS higher |
| Debt / equity as of 2026-09-03 | 0.83 | 0.00 | NERV lower |
| Revenue growth (YoY) as of 2026-09-03 | +10.8% | n/a | |
| Revenue CAGR (3y) SEC XBRL | +9.9% | n/a | |
| Dividend streak (yrs) SEC XBRL | 0 | 0 | Tie |
| Beta as of 2026-09-03 | 0.70 | 0.80 | |
| 1-year return as of 2026-10-08 close | +27.3% | +13.8% | ALKS higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.